How to get semaglutide prescribed is straightforward: start with a primary care clinician, an obesity-medicine or endocrinology clinic, a legitimate telehealth service, or a manufacturer-supported prescriber channel. In every route, a clinician must review your medical history, confirm that semaglutide fits an appropriate indication, and write a prescription before a pharmacy can dispense it. A website that skips that review is not an online shortcut to the same care.
The important choice is not simply online versus in person. It is brand versus compounded medication, insurance versus self-pay, and a real prescribing relationship versus an anonymous vial.
How to get semaglutide prescribed: four routes
| Route | Who evaluates the request | What happens after approval |
|---|---|---|
| Primary care | A physician, nurse practitioner or physician assistant familiar with the patient’s history | A brand prescription usually goes to a retail or mail-order pharmacy |
| Obesity-medicine or endocrinology clinic | A clinician focused on weight management, diabetes or metabolic care | The clinic may handle prior authorization and follow-up |
| Licensed telehealth | A provider licensed where the patient is located | A brand prescription goes to a pharmacy, or an individual compounded prescription is sent to a compounding pharmacy |
| Manufacturer-supported channel | A connected prescriber evaluates the patient, or an existing prescriber sends a valid prescription | The manufacturer’s pharmacy channel dispenses and ships the brand product |
A retail pharmacy does not originate the prescription. Searching for “semaglutide near me” may locate a pharmacy or clinic, but the pharmacy still needs an order from a licensed prescriber. The same clinical gate applies to online semaglutide. Novo Nordisk’s NovoCare Pharmacy page, reviewed August 17, 2026, says both its self-pay and insurance routes require a prescription and offers home delivery after that prescription is received.
People deciding between the two best-known GLP-1 options can use the separate guide to getting tirzepatide prescribed; the screening overlaps, but the products and indications are not interchangeable.
Who may qualify for a semaglutide prescription
Eligibility starts with the reason for treatment. For chronic weight management, the current Wegovy prescribing information covers adults with obesity, or adults with overweight plus at least one weight-related condition. Type 2 diabetes, established cardiovascular disease and certain liver disease can change which branded product or indication a clinician considers. Wanting weight loss by itself is not a guarantee of a prescription.
The evidence also explains why an intake asks for more than a goal weight. In STEP 1, published in the New England Journal of Medicine in 2021, 1,961 adults without diabetes entered with a body-mass index of at least 30, or at least 27 plus a weight-related condition. At week 68, mean weight change was −14.9% with semaglutide and −2.4% with placebo (Wilding et al.). SELECT studied a different population: 17,604 adults age 45 or older with established cardiovascular disease, BMI of at least 27 and no diabetes. The trial reported a 20% relative reduction in its primary cardiovascular endpoint, a hazard ratio of 0.80 (Lincoff et al., NEJM 2023). Those populations are specific; they are not evidence that semaglutide suits everyone.
What the medical intake actually asks
A credible semaglutide intake is detailed because the answer can change with one item. Expect questions in these areas:
| Intake topic | Why the provider needs it |
|---|---|
| Height, weight and treatment goal | Establishes whether the request matches a recognized indication |
| Diabetes, blood pressure, cholesterol and cardiovascular history | Defines the clinical context and which product may fit |
| Personal or family history of medullary thyroid carcinoma or MEN 2 | The Wegovy label lists both as contraindications |
| Pregnancy, breastfeeding or plans for pregnancy | The label gives pregnancy-specific warnings and timing considerations |
| Pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal symptoms or diabetic retinopathy | These conditions may alter the risk assessment and monitoring plan |
| Current medicines and allergies | Other semaglutide or GLP-1 products, insulin, sulfonylureas and prior serious hypersensitivity matter |
| Planned anesthesia or deep sedation | Delayed gastric emptying affects peri-procedure planning |
The provider may ask follow-up questions or request recent records or laboratory work. That is a sign the intake is being used to make a decision, not a formality. The prescriber sets the formulation and actual dose; an advertisement or general chart does not.
Prescribed online versus simply sold online
A legitimate telehealth visit is still medical care. The service confirms identity and location, routes the case to a clinician licensed in that state, identifies the dispensing pharmacy, and provides a way to reach the clinical team after shipment. The product label should identify what was dispensed, its concentration when applicable, the patient, prescriber and pharmacy.
A checkout page that promises approval, hides the pharmacy, or presents a compounded vial as the brand removes those safeguards. In March 2026, the FDA warned 30 telehealth companies over false or misleading GLP-1 marketing, including claims of sameness with brand products and unclear sourcing.
Promise semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medication is also not a generic brand product. A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision belongs to the patient and the doctor. The compounded semaglutide guide explains that distinction in more depth.
What happens after a Promise intake
The intake collects the GLP-1-specific history above. At Promise, a licensed provider reviews every request and may prescribe only when medically appropriate; not everyone qualifies. If the provider writes a prescription, a licensed U.S. compounding pharmacy prepares and dispenses it for that patient. The clinical relationship continues for questions and follow-up rather than ending at checkout.
The walkthrough of what to expect from a first visit covers the handoff from questionnaire to review. State licensure is part of that process, not a technical detail: telehealth prescribers must be licensed where the patient is located.
What arrives and how it gets there
A brand route supplies sealed manufacturer packaging through a retail, mail-order or manufacturer-supported pharmacy. A compounded route supplies a pharmacy-labeled preparation made for the named patient, with the prescribed directions, concentration, storage information and administration supplies when applicable. The telehealth company should not be the mystery source of an unmarked vial.
Shipping conditions matter for injectable products. The FDA’s current GLP-1 safety page, reviewed August 17, 2026, reports complaints about injectable compounded GLP-1 products arriving warm or without adequate cold packs and advises against using a shipment that arrives that way. The dispensing pharmacy is the right contact for a temperature or packaging problem.
Insurance, self-pay and the real point of comparison
An in-person prescription is not automatically covered, and an online prescription is not automatically self-pay. Brand coverage depends on the plan, indication and any prior-authorization requirements. NovoCare offers a direct self-pay route for brand semaglutide, but its prices vary by formulation, dose and program terms; the live manufacturer page is more reliable than a copied price. Compounded care is commonly paid directly.
The useful comparison includes who reviews the case, which pharmacy dispenses, what product is being supplied, how questions are handled and what the total price includes. A low vial price without a named prescriber or pharmacy is not the same service at a discount.
The checks that matter before choosing a route
A sound route can answer five questions plainly: Who is the licensed prescriber? Is that person licensed in the patient’s state? Which pharmacy will dispense? Is the product a manufacturer brand or a patient-specific compounded preparation? What happens if the provider declines or the shipment has a problem?
Those answers are what turn a semaglutide prescription into accountable care. The intake may take longer than a checkout form, but the clinician’s ability to say no is the part worth keeping.